Results 171 to 180 of about 168,682 (384)

TLR9 ligand induces the generation of CD20+ plasmablasts and plasma cells from CD27+ memory B-cells

Frontiers in Immunology, 2011
Plasma cells have a heterogeneous phenotype in humans. While bone marrow plasma cells are CD20-CD138+, tonsil plasma cells are CD20+CD138+/- and peripheral plasmablasts are CD20-CD138-.
Alexandrine eGeffroy-Luseau, Alexandrine eGeffroy-Luseau, David eChiron, David eChiron, Géraldine eDescamps, Géraldine eDescamps, Gaëtan eJégo, Gaëtan eJégo, Martine eAmiot, Martine eAmiot, Catherine ePellat-Deceunynck, Catherine ePellat-Deceunynck   +11 more
doaj   +1 more source

Differences in Dynamics of Specific Antinuclear Antibodies and Their Susceptibility to B Cell–Targeting Treatment in Patients With Systemic Lupus Erythematosus

Arthritis &Rheumatology, EarlyView.
Objective The presence of antinuclear antibodies (ANAs) is characteristic for systemic lupus erythematosus (SLE). Antibody dynamics over time are thought to reflect the cellular source of ANAs and their therapeutic targetability. Anti–double‐stranded DNA (anti‐dsDNA) is the most prevalent and well‐studied of all ANAs, and fluctuations in anti‐dsDNA ...
Hugo J. van Dooren, Mieke van Schaik, Annemarie L. Dorjée, Eline J. Arends, Meggan Mackay, Laura Cooney, David A. Fox, David Wofsy, Dawn Smilek, Cynthia Aranow, Maria Dall'Era, Tom W. J. Huizinga, Cees van Kooten, René E. M. Toes, Betty Diamond, Y. K. Onno Teng, Jolien Suurmond   +16 more
wiley   +1 more source

Targeting CD20 takes the backseat in CLL [PDF]

Blood, 2019
In this issue of Blood , Burger and colleagues report results from a randomized phase 2 study combining rituximab and ibrutinib vs ibrutinib alone in high-risk, untreated, and previously treated chronic lymphocytic leukemia (CLL) patients. 1 This well-performed study provides clear guidance to the field of CLL that, unlike chemotherapy, rituximab ...
openaire   +3 more sources

The Effect of Histological CD20-Positive B Cell Infiltration in Acute Cellular Rejection on Kidney Transplant Allograft Survival

Journal of Immunology Research, 2016
Background. It is controversial whether lymphocyte infiltration exhibited in biopsy specimens is associated with transplant outcomes. This study focused on the effect of CD20-positive B cell infiltration in biopsy specimens from allografts with acute ...
Yan Jiang, Rending Wang, Huiping Wang, Hongfeng Huang, Wenhan Peng, Wenxian Qiu, Jingyi Zhou, Jianghua Chen   +7 more
doaj   +1 more source

Antiphospholipid Syndrome: An Antibody‐Mediated Disease With Emerging Therapeutic Opportunities

Arthritis &Rheumatology, EarlyView.
Antiphospholipid syndrome (APS) is an autoimmune thromboinflammatory disease characterized by vascular thrombosis, pregnancy morbidity, and other manifestations driven by antiphospholipid autoantibodies. In this review, we present a clinical case that illustrates some diagnostic and therapeutic challenges in managing severe, relapsing APS ...
Thalia G. Newman, Jason S. Knight
wiley   +1 more source

Reduction of tumor burden and stabilization of disease by systemic therapy with anti-CD20 antibody (rituximab) in patients with primary cutaneous B-cell lymphoma [PDF]

, 2000
Lucie Heinzerling, Margarete Urbanek, Jens Oliver Funk, Stefan Peker, O. Bleck, K. Neuber, G�nter Burg, Peter Von Den Driesch, Reinhard Dummer   +8 more
openalex   +1 more source

Very low doses of rituximab in autoimmune hemolytic anemia—an open-label, phase II pilot trial

Frontiers in Medicine
IntroductionAlthough rituximab is approved for several autoimmune diseases, no formal dose finding studies have been conducted. The amount of CD20+ cells differs significantly between autoimmune diseases and B-cell malignancies.
Miriam M. Moser, Renate Thalhammer, Christian Sillaber, Ulla Derhaschnig, Christa Firbas, Ulrich Jäger, Bernd Jilma, Christian Schoergenhofer   +7 more
doaj   +1 more source

B cells and systemic sclerosis interstitial lung disease

Arthritis &Rheumatology, Accepted Article.
Interstitial lung disease is an important complication of systemic sclerosis (SSc‐ILD) with high mortality and morbidity. Recent clinical studies in SSc‐ILD have led to FDA‐approved therapies in SSc‐ILD. Importantly, evidence from these studies has been extrapolated to guide management of interstitial lung diseases of other systemic autoimmune ...
Nina Goldman, Voon Ong, Christopher Denton   +2 more
wiley   +1 more source

Low RYR2 Level Relates to Poor Prognosis of Patients With Lung Adenocarcinoma by Promoting Tumor Cell Proliferation and Inhibiting Immune Cell Infiltration

Biotechnology and Applied Biochemistry, EarlyView.
ABSTRACT Ryanodine receptor type 2 (RYR2) is a large calcium channel that has been identified as one of the most frequently mutated genes in lung adenocarcinoma (LUAD). Despite its potential significance, the role of RYR2 in LUAD remains poorly understood.
Tao Wang, Baozhen Wang, Zhongting Lu, Tao Li   +3 more
wiley   +1 more source

CD20-Positive Peripheral T-Cell Lymphoma: Report of a Case after Nodular Sclerosis Hodgkin's Disease and Review of the Literature [PDF]

, 2000
Renee L. Mohrmann, Daniel A. Arber
openalex   +1 more source